Translational and Clinical Research (TACR)

项目摘要/摘要(翻译和临床研究) 转化和临床研究(TACR)计划促进实验室之间的合作- 密歇根大学跨实体肿瘤疾病部位的翻译-临床研究连续体 M)罗杰尔癌症中心(Rogel)。TACR代表了Rogel的一个关键的桥梁机制，将其 以实验室和人口科学为基础的研究计划，产生创新的概念、试剂和 TACR转化为以实体肿瘤患者为导向的研究的方法。TACR计划由以下部分组成 79名成员来自15个不同的部门和4个不同的学校和学院。2022年，TACR计划 会员每年与癌症相关的直接资助总额为2080万美元，其中750万美元(36%)来自NCI； 该计划的同行评审资金总额为1020万美元(49%)。此外，TACR成员拥有1060万美元 来自非同行和行业赞助商的赠款。会员共有出版物1457份，其中30.1%为 方案内协作占34.8%，方案间协作占34.8%。TACR计划有三个具体的 目标：1)开发和应用最先进的分子靶向方法来诊断和治疗癌症； 2)开发和测试新的预测生物标记物和跨肿瘤类型的疾病监测策略；以及3) 从罗杰尔癌症中心的科学计划到有影响力的临床试验的先进概念。

PROJECT SUMMARY/ABSTRACT (TRANSLATIONAL AND CLINICAL RESEARCH) The Translational and Clinical Research (TACR) Program catalyzes collaborations along the laboratory- translational-clinical research continuum and across solid tumor disease sites in the University of Michigan (U- M) Rogel Cancer Center (Rogel). TACR represents a crucial bridging mechanism for the Rogel, linking its laboratory and population science based-research programs that generate innovative concepts, agents, and approaches that TACR translates to solid tumor patient-oriented research. The TACR Program is comprised of 79 members from 15 different departments and four different schools and colleges. In 2022, TACR Program members had a total of $20.8M in annual direct cancer-relevant funding, of which $7.5M (36%) was from NCI; the Program had a total of $10.2M (49%) in peer-reviewed funding. In addition, TACR members had $10.6 million in grants from non-peer and industry sponsors. Members have a total of 1457 publications, of which 30.1% are intra-programmatic and 34.8% are inter-programmatic collaborations. The TACR program has three Specific Aims: 1) Develop and apply state-of-the-art molecularly targeted approaches to cancer diagnosis and treatment; 2) Develop and test new predictive biomarker and disease-monitoring strategies across tumor types; and 3) Advance concepts emanating from Rogel Cancer Center scientific programs to impactful clinical trials.